Seagal
Well-Known Member
Similar to T’s decline with age, DHEAS and androstenediones production also decreases with age [3]. This decline in proandrogens markedly reduces the amount of T available at the cellular level. While androstenedione is found in 5–10-fold higher concentrations than T in serum, DHEAS levels may be thousands of times higher than T levels [4]. Thus, in comparison to T, the contribution of these prohormones to bioavailable T at the AR exponentially declines with age. With this marked decline in local production, increasing amounts of T (i.e., from replacement therapy) would be needed to supply a greater portion of bioavailable T to the AR. There is also concern of AR ‘resistance’ [29]. Theoretically, with aging the AR, similar to the insulin receptor, may become resistant to T and require higher levels to elicit the same response.Take a look at Rebecca Glaser and women and learn a little bit.
...
We no longer routinely monitor serum T levels in all patients. However, because of aromatization and the adverse effects of excess estrogen in men and some women, we do measure estradiol and testosterone levels in subgroups of patients. Patients are treated with aromatase inhibitors, combined in the pellet implant based on history (e.g., breast cancer, endometriosis, fibroids etc.), symptoms (e.g., fluid retention, weight gain, anxiety etc.) and serum levels [11].